These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 6134623)

  • 1. Analytical model of some pharmacokinetic and pharmacodynamic properties of fazadinium in man.
    d'Hollander AA; Delcroix C; Duvaldestin P; Henzel D; Coussaert E; Desmonts JM
    Eur J Clin Pharmacol; 1983; 24(3):407-13. PubMed ID: 6134623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between decay of plasma concentration of fazadinium and recovery from its neuromuscular blocking effect.
    d'Hollander AA; Duvaldestin P; Henzel D; Delcroix C; Desmonts JM
    Br J Anaesth; 1981 Aug; 53(8):853-8. PubMed ID: 6115662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on fazadinium bromide (ah 8165): a new non-depolarizing neuromuscular blocking agent.
    Hughes R; Payne JP; Sugai N
    Can Anaesth Soc J; 1976 Jan; 23(1):36-47. PubMed ID: 2378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetics of fazadinium.
    Bevan DR; D'Souza J; Rouse JM; Caldwell J; Smith RL
    Anaesthesia; 1980 Sep; 35(9):873-8. PubMed ID: 6108730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics and pharmacodynamics of fazadinium in renal failure.
    Bevan DR; D'Souza JD; Rouse JM; Caldwell J; Smith RL
    Eur J Clin Pharmacol; 1981; 20(4):293-8. PubMed ID: 6118278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between pharmacokinetics and pharmacodynamics of fazadinium in rabbits.
    Dominguez-Gil AA; Cepeda M; Muriel C; Calvo JI; Dominguez-Gil A; Alonso AC
    Arzneimittelforschung; 1981; 31(11):1913-7. PubMed ID: 6119095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of fazadinium in man.
    Duvaldestin P; Henzel D; Demetriou M; Desmonts JM
    Br J Anaesth; 1978 Aug; 50(8):773-7. PubMed ID: 28133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors limiting the rate of termination of the neuromuscular blocking action of fazadinium dibromide.
    Tyers MB
    Br J Pharmacol; 1978 Jun; 63(2):287-93. PubMed ID: 27272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fazadinium and pancuronium: a pharmacodynamic study.
    Hull CJ; English MJ; Sibbald A
    Br J Anaesth; 1980 Dec; 52(12):1209-21. PubMed ID: 6108777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An analytical pharmacodynamic model for nondepolarizing neuromuscular blocking agents.
    d'Hollander A; Delcroix C
    J Pharmacokinet Biopharm; 1981 Feb; 9(1):27-40. PubMed ID: 6453216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of single twitch and train-of-four responses and of tetanic fade in relation to plasma concentrations of fazadinium in man.
    d'Hollander AA; Duvaldestin P; Delcroix C; Nevelsteen M; Desmonts JM
    Anesth Analg; 1982 Mar; 61(3):225-30. PubMed ID: 6121521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of fazadinium in patients with renal failure.
    Duvaldestin P; Bertrand JC; Concina D; Henzel D; Lareng L; Desmonts JM
    Br J Anaesth; 1979 Oct; 51(10):943-7. PubMed ID: 42420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuromuscular blockade of fazadinium bromide (AH 8165) in renal failure patients.
    Camu F; D'Hollander A
    Acta Anaesthesiol Scand; 1978; 22(3):221-6. PubMed ID: 27936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fazadinium pharmacokinetics in patients with liver disease.
    Duvaldestin P; Saada J; Henzel D; Saumon G
    Br J Anaesth; 1980 Aug; 52(8):789-94. PubMed ID: 6107098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorimetric determination and pharmacokinetic studies of fazadinium bromide in dogs.
    Pastorino AM
    Arzneimittelforschung; 1978; 28(10):1728-30. PubMed ID: 39568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative evaluation of neuromuscular blockade and reversibility of AH 8165 and pancuronium bromide in man.
    Camu F; Sanders M; D'Hollander A
    Acta Anaesthesiol Belg; 1976; 27 suppl():80-5. PubMed ID: 13601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of speed of onset of fazadinium, pancuronium, tubocurarine and suxamethonium.
    Blackburn CL; Morgan M
    Br J Anaesth; 1978 Apr; 50(4):361-4. PubMed ID: 26369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetic analysis of the AH8165-receptor interaction at the mammalian neuromuscular junction.
    Waud BE
    Anesthesiology; 1977 Feb; 46(2):94-6. PubMed ID: 13684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AH 8165: a new short-acting, competitive neuromuscular blocking drug.
    Brittain RT; Tyers MB
    Br J Pharmacol; 1972 May; 45(1):158P-159P. PubMed ID: 4625270
    [No Abstract]   [Full Text] [Related]  

  • 20. Rate of recovery from fazadinium: relationship to the rate of decline of its plasma concentration.
    Ramzan IM
    J Pharm Sci; 1983 Nov; 72(11):1369-70. PubMed ID: 6139474
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.